Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

149 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene.
Baldazzi C, Iacobucci I, Luatti S, Ottaviani E, Marzocchi G, Paolini S, Stacchini M, Papayannidis C, Gamberini C, Martinelli G, Baccarani M, Testoni N. Baldazzi C, et al. Among authors: papayannidis c. Leuk Res. 2010 Oct;34(10):e282-5. doi: 10.1016/j.leukres.2010.05.009. Epub 2010 Jun 9. Leuk Res. 2010. PMID: 20594995 No abstract available.
Prospective multicenter study on infectious complications and clinical outcome of 230 unfit acute myeloid leukemia patients receiving first-line therapy with hypomethylating agents alone or in combination with Venetoclax.
Candoni A, Lazzarotto D, Papayannidis C, Piccini M, Nadali G, Dargenio M, Riva M, Fracchiolla N, Mellillo L, Dragonetti G, Del Principe MI, Cattaneo C, Stulle M, Pasciolla C, De Marchi R, Delia M, Tisi MC, Bonuomo V, Sciumè M, Spadea A, Sartor C, Griguolo D, Buzzatti E, Basilico CM, Sarlo C, Piccioni AL, Cerqui E, Lessi F, Olivieri A, Fanin R, Luppi M, Pagano L. Candoni A, et al. Among authors: papayannidis c. Am J Hematol. 2023 Apr;98(4):E80-E83. doi: 10.1002/ajh.26846. Epub 2023 Feb 9. Am J Hematol. 2023. PMID: 36651870 Free article. No abstract available.
Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study.
Fracchiolla NS, Sciumè M, Papayannidis C, Vitale A, Chiaretti S, Annunziata M, Giglio F, Salutari P, Forghieri F, Lazzarotto D, Lunghi M, Imovilli A, Scappini B, Bonifacio M, Dargenio M, Gurrieri C, Todisco E, Defina M, Del Principe MI, Zappasodi P, Cerrano M, Santoro L, Tagliaferri E, Barozzi E, De Roberto P, Canzi M, Buzzatti E, Sartor C, Passamonti F, Foà R, Curti A. Fracchiolla NS, et al. Among authors: papayannidis c. Cancers (Basel). 2023 Sep 19;15(18):4623. doi: 10.3390/cancers15184623. Cancers (Basel). 2023. PMID: 37760592 Free PMC article.
Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive disease.
Kayser S, Sartor C, Giglio F, Bruno A, Webster J, Chiusolo P, Saraceni F, Guerzoni S, Pochintesta L, Borlenghi E, Marconi G, Zacheo I, Cerrano M, Salutari P, Restuccia F, Abbenante M, Levis MJ, Schlenk RF, Papayannidis C. Kayser S, et al. Among authors: papayannidis c. Haematologica. 2024 May 1;109(5):1385-1392. doi: 10.3324/haematol.2023.284310. Haematologica. 2024. PMID: 38058184 Free PMC article.
Does Cytokine-Release Syndrome Induced by CAR T-Cell Treatment Have an Impact on the Pharmacokinetics of Meropenem and Piperacillin/Tazobactam in Patients with Hematological Malignancies? Findings from an Observational Case-Control Study.
Liu C, Cojutti PG, Giannella M, Roberto M, Casadei B, Cristiano G, Papayannidis C, Vianelli N, Zinzani PL, Viale P, Bonifazi F, Pea F. Liu C, et al. Among authors: papayannidis c. Pharmaceutics. 2023 Mar 22;15(3):1022. doi: 10.3390/pharmaceutics15031022. Pharmaceutics. 2023. PMID: 36986882 Free PMC article.
BH3 mimetics in relapsed and refractory adult acute lymphoblastic leukemia: a Campus ALL real-life study.
Malfona F, Tanasi I, Piccini M, Papayannidis C, Federico V, Mancini V, Roncoroni E, Todisco E, Bianchi S, Ciotti G, Chiusolo P, Gentile M, Gianfelici V, Giglio F, Malagola M, Mulé A, Saraceni F, Vetro C, Zallio F, Cappelli LV, Pizzolo G, Foà R, Bonifacio M, Chiaretti S. Malfona F, et al. Among authors: papayannidis c. Haematologica. 2024 Mar 1;109(3):988-993. doi: 10.3324/haematol.2023.283684. Haematologica. 2024. PMID: 37794811 Free PMC article. No abstract available.
SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted.
Mancini M, Monaldi C, De Santis S, Papayannidis C, Rondoni M, Sartor C, Bruno S, Pagano L, Criscuolo M, Zanotti R, Bonifacio M, Tosi P, Arock M, Valent P, Cavo M, Soverini S. Mancini M, et al. Among authors: papayannidis c. Biomark Res. 2023 Mar 10;11(1):29. doi: 10.1186/s40364-023-00468-7. Biomark Res. 2023. PMID: 36894973 Free PMC article.
Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.
Pabst T, Vey N, Adès L, Bacher U, Bargetzi M, Fung S, Gaidano G, Gandini D, Hultberg A, Johnson A, Ma X, Müller R, Nottage K, Papayannidis C, Recher C, Riether C, Shah P, Tryon J, Xiu L, Ochsenbein AF. Pabst T, et al. Among authors: papayannidis c. Haematologica. 2023 Jul 1;108(7):1793-1802. doi: 10.3324/haematol.2022.281563. Haematologica. 2023. PMID: 36779592 Free PMC article. Clinical Trial.
149 results